The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
 
Adam Jacob Schoenfeld
(OPTIONAL) Uncompensated Relationships - Iovance Biotherapeutics
 
Mehmet Altan
Consulting or Advisory Role - GlaxoSmithKline; Shattuck Labs
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Eisai; EMD Serono; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Wells Fargo; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Sandra P. D'Angelo
Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
 
Brian H. Ladle
No Relationships to Disclose
 
Jonathan Christopher Noujaim
Consulting or Advisory Role - Bayer
 
Kai He
Consulting or Advisory Role - Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Mirati Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst)
 
David A. Liebner
Consulting or Advisory Role - Blueprint Medicines; Epizyme; Foundation Medicine
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
Travel, Accommodations, Expenses - Blueprint Medicines; Epizyme; Foundation Medicine
 
Adrian G. Sacher
Honoraria - Amgen; AstraZeneca; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Gritstone Bio; Pfizer
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Jeffrey Yachnin
No Relationships to Disclose
 
Chao H. Huang
Stock and Other Ownership Interests - Vanguard Funds
Honoraria - Ipsen
Consulting or Advisory Role - Biodesix; Ipsen
Research Funding - Bayer (Inst); Benta Pharma Industries (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Regenxbio (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Apexigen; Bayer; Cytokinetics; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeuticuses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly
 
Aisha N. Hasan
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
 
Thomas H. Faitg
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Emily Butler
No Relationships to Disclose
 
Aiman Shalabi
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - GlaxoSmithKline
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Dejka M. Araujo
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Immatics (Inst)